Entrada Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Entrada Therapeutics
TRDA Stock  USD 10.46  0.35  3.24%   
Entrada Therapeutics financial statements provide useful quarterly and yearly information to potential Entrada Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Entrada Therapeutics financial statements helps investors assess Entrada Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Entrada Therapeutics' valuation are summarized below:
Gross Profit
85.5 M
Profit Margin
0.3114
Market Capitalization
406.4 M
Enterprise Value Revenue
0.2199
Revenue
210.8 M
We have found one hundred twenty available fundamental signals for Entrada Therapeutics, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to verify all of Entrada Therapeutics prevailing market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. The current year's Market Cap is expected to grow to about 659.7 M, whereas Enterprise Value is forecasted to decline to about 585 M.

Entrada Therapeutics Total Revenue

221.32 Million

Check Entrada Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Entrada Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 20.4 M, Interest Income of 20.4 M or Depreciation And Amortization of 3.4 M, as well as many indicators such as Price To Sales Ratio of 3.81, Dividend Yield of 0.0 or PTB Ratio of 1.58. Entrada financial statements analysis is a perfect complement when working with Entrada Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Entrada Therapeutics Correlation against competitors.
For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.

Entrada Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets296.1 M526.3 M129.7 M
Slightly volatile
Total Current Liabilities42.6 M39.5 M18.3 M
Slightly volatile
Other Liabilities228.2 K455.4 K153.6 K
Slightly volatile
Property Plant And Equipment Net86.2 M82 M19.5 M
Slightly volatile
Accounts Payable3 M4.3 M1.6 M
Slightly volatile
Cash102.8 M101.2 M51 M
Slightly volatile
Non Current Assets Total43.9 M86.3 M18.2 M
Slightly volatile
Cash And Short Term Investments213.4 M420 M95.6 M
Slightly volatile
Common Stock Shares Outstanding36.1 M39 M32.2 M
Slightly volatile
Liabilities And Stockholders Equity296.1 M526.3 M129.7 M
Slightly volatile
Non Current Liabilities Total47.2 M58.2 M37 M
Slightly volatile
Other Current Assets10.7 M16.4 M4.7 M
Slightly volatile
Other Stockholder Equity399.6 M558.1 M161.5 M
Slightly volatile
Total Liabilities89.8 M97.6 M55.2 M
Slightly volatile
Property Plant And Equipment Gross96 M91.5 M21.3 M
Slightly volatile
Total Current Assets252.2 M440 M111.6 M
Slightly volatile
Non Current Liabilities Other15.2 K17.1 K18.6 K
Slightly volatile
Net Working Capital209.6 M400.6 M93.3 M
Slightly volatile
Common Stock2.8 K4 K1.7 K
Slightly volatile
Property Plant Equipment39.9 M38 M10.1 M
Slightly volatile
Other Assets0.860.920.1 M
Pretty Stable
Net Receivables3.8 M3.7 M1.9 M
Slightly volatile
Common Stock Total Equity2.4 K2.7 K2.9 K
Slightly volatile
Capital Surpluse313.9 M353.1 M385 M
Slightly volatile
Short and Long Term Debt Total56.2 M59.2 M32.6 M
Slightly volatile
Short Term Debt10.5 M7.6 M15.7 M
Slightly volatile
Current Deferred Revenue13 M13.7 M117.4 M
Slightly volatile
Inventory0.80.90.9813
Slightly volatile

Entrada Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income20.4 M19.5 M4.1 M
Slightly volatile
Depreciation And Amortization3.4 M3.3 M869.8 K
Slightly volatile
Selling General Administrative23.1 M38.5 M11.3 M
Slightly volatile
Other Operating Expenses88.5 M163.8 M42.4 M
Slightly volatile
Research Development65.5 M125.3 M31 M
Slightly volatile
Cost Of Revenue120.6 M114.9 M21.2 M
Slightly volatile
Total Operating Expenses88.5 M163.8 M42.4 M
Slightly volatile
Reconciled Depreciation4 M3.8 M921.5 K
Slightly volatile
Selling And Marketing Expenses0.80.90.9813
Slightly volatile

Entrada Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation18.8 M17.9 M4.1 M
Slightly volatile
Begin Period Cash Flow90.9 M71.6 M52.6 M
Slightly volatile
Other Cashflows From Financing Activities3.2 M3.4 M11 M
Pretty Stable
Capital Expenditures3.5 M3.2 M1.8 M
Slightly volatile
Total Cash From Financing Activities88.4 M103 M35.7 M
Slightly volatile
End Period Cash Flow105 M105.2 M51.8 M
Slightly volatile
Change To Liabilities6.4 M6.1 M1.9 M
Slightly volatile
Sale Purchase Of Stock545.3 K574 K143.4 M
Slightly volatile
Cash And Cash Equivalents Changes201.6 M226.8 M247.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.813.06023.8119
Slightly volatile
Days Sales Outstanding12.656.372515.74
Slightly volatile
Stock Based Compensation To Revenue0.10.0850.1005
Slightly volatile
EV To Sales3.712.86093.7975
Slightly volatile
Payables Turnover28.827.435.6423
Slightly volatile
Sales General And Administrative To Revenue0.240.18250.2454
Slightly volatile
Research And Ddevelopement To Revenue0.750.59450.7615
Slightly volatile
Capex To Revenue0.01420.0150.0399
Slightly volatile
Cash Per Share11.8211.25813.4825
Slightly volatile
Days Payables Outstanding13.0813.771.8 K
Slightly volatile
Current Ratio16.2111.145311.6472
Pretty Stable
Receivables Turnover31.6957.277724.7654
Slightly volatile
Graham Number17.0619.1920.926
Slightly volatile
Debt To Equity0.140.13810.1341
Slightly volatile
Capex Per Share0.07840.08470.053
Slightly volatile
Revenue Per Share3.825.654.0075
Slightly volatile
Interest Debt Per Share1.221.5871.0462
Slightly volatile
Debt To Assets0.0960.11250.1057
Slightly volatile
Operating Cycle12.656.372515.74
Slightly volatile
Days Of Payables Outstanding13.0813.771.8 K
Slightly volatile
Pretax Profit Margin0.160.31540.1115
Slightly volatile
Effective Tax Rate0.01230.01290.1604
Pretty Stable
Long Term Debt To Capitalization0.0880.09680.1056
Slightly volatile
Total Debt To Capitalization0.120.12140.1172
Slightly volatile
Debt Equity Ratio0.140.13810.1341
Slightly volatile
Quick Ratio16.2111.145311.6472
Pretty Stable
Cash Ratio2.442.56359.382
Very volatile
Days Of Sales Outstanding12.656.372515.74
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.161.0761.0619
Pretty Stable
Fixed Asset Turnover1.582.5691.4773
Slightly volatile
Debt Ratio0.0960.11250.1057
Slightly volatile
Price Sales Ratio3.813.06023.8119
Slightly volatile
Asset Turnover0.270.40050.2825
Slightly volatile
Gross Profit Margin0.180.20.2213
Slightly volatile

Entrada Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap659.7 M645 M687.1 M
Slightly volatile
Enterprise Value585 M603 M647.5 M
Slightly volatile

Entrada Fundamental Market Drivers

Forward Price Earnings3333.3333
Cash And Short Term Investments420 M

Entrada Upcoming Events

4th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Entrada Therapeutics Financial Statements

Entrada Therapeutics stakeholders use historical fundamental indicators, such as Entrada Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Entrada Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Entrada Therapeutics' assets and liabilities are reflected in the revenues and expenses on Entrada Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Entrada Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue13.7 M13 M
Total Revenue210.8 M221.3 M
Cost Of Revenue114.9 M120.6 M
Stock Based Compensation To Revenue 0.08  0.10 
Sales General And Administrative To Revenue 0.18  0.24 
Research And Ddevelopement To Revenue 0.59  0.75 
Capex To Revenue 0.01  0.01 
Revenue Per Share 5.65  3.82 
Ebit Per Revenue 0.22  0.23 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CRMSalesforce
CRMSalesforce
When determining whether Entrada Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Entrada Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Entrada Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Entrada Therapeutics Stock:
How To Invest In Entrada
Details
Is Entrada Stock a good investment?
Details
What is Entrada Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Entrada Therapeutics Correlation against competitors.
For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.
You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entrada Therapeutics. If investors know Entrada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entrada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
1.68
Revenue Per Share
5.65
Quarterly Revenue Growth
(0.11)
Return On Assets
0.059
Return On Equity
0.1956
The market value of Entrada Therapeutics is measured differently than its book value, which is the value of Entrada that is recorded on the company's balance sheet. Investors also form their own opinion of Entrada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Entrada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entrada Therapeutics' market value can be influenced by many factors that don't directly affect Entrada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Entrada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Entrada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entrada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY